Next Article in Journal
Sequencing and Phylogenetic Analysis of Chloroplast Genes in Freshwater Raphidophytes
Next Article in Special Issue
Golgi Oncoprotein GOLPH3 Gene Expression Is Regulated by Functional E2F and CREB/ATF Promoter Elements
Previous Article in Journal
Droplet Digital PCR Detection of the Erythropoietin Transgene from Horse Plasma and Urine for Gene-Doping Control
Previous Article in Special Issue
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?

MYC Oncogene Contributions to Release of Cell Cycle Brakes

Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) CSIC-Universidad de Cantabria and Department of Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain
Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland
Author to whom correspondence should be addressed.
Genes 2019, 10(3), 244;
Received: 24 February 2019 / Revised: 16 March 2019 / Accepted: 18 March 2019 / Published: 22 March 2019
(This article belongs to the Special Issue Cell Cycle and Regulation)
Promotion of the cell cycle is a major oncogenic mechanism of the oncogene c-MYC (MYC). MYC promotes the cell cycle by not only activating or inducing cyclins and CDKs but also through the downregulation or the impairment of the activity of a set of proteins that act as cell-cycle brakes. This review is focused on the role of MYC as a cell-cycle brake releaser i.e., how MYC stimulates the cell cycle mainly through the functional inactivation of cell cycle inhibitors. MYC antagonizes the activities and/or the expression levels of p15, ARF, p21, and p27. The mechanism involved differs for each protein. p15 (encoded by CDKN2B) and p21 (CDKN1A) are repressed by MYC at the transcriptional level. In contrast, MYC activates ARF, which contributes to the apoptosis induced by high MYC levels. At least in some cells types, MYC inhibits the transcription of the p27 gene (CDKN1B) but also enhances p27’s degradation through the upregulation of components of ubiquitin ligases complexes. The effect of MYC on cell-cycle brakes also opens the possibility of antitumoral therapies based on synthetic lethal interactions involving MYC and CDKs, for which a series of inhibitors are being developed and tested in clinical trials. View Full-Text
Keywords: MYC; cell cycle; CDK inhibitors; p21; p27; p15; ARF MYC; cell cycle; CDK inhibitors; p21; p27; p15; ARF
Show Figures

Figure 1

MDPI and ACS Style

García-Gutiérrez, L.; Delgado, M.D.; León, J. MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes 2019, 10, 244.

AMA Style

García-Gutiérrez L, Delgado MD, León J. MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes. 2019; 10(3):244.

Chicago/Turabian Style

García-Gutiérrez, Lucía, María D. Delgado, and Javier León. 2019. "MYC Oncogene Contributions to Release of Cell Cycle Brakes" Genes 10, no. 3: 244.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop